Kamalram Thippu Jayaprakash
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kamalram Thippu Jayaprakash has a total of 210 co-authors. Here are the top co-authors by number of shared publications:
R. Shaffer
6 shared publications- Andrew Nisbet
Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom
4 shared publications Alison Falconer
Department of Oncology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK
3 shared publicationsGail Horan
Department of Oncology, Addenbrooke’s Hospital, Cambridge, UK
3 shared publicationsJohanna Sukumar
Imperial Prostate, Divison of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK
3 shared publicationsK. Wildschut
3 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in Lung Cancer
- Vol. 222
Lung cancer associated with cystic airspaces (LCCA): A comprehensive literature review undertaken as part of the British thoracic oncology group (BTOG) work programme
- 23 October 2026
- Published by Elsevier in Lung Cancer
- Vol. 222
Open AccessLung cancer associated with cystic airspaces (LCCA): A comprehensive literature review undertaken as part of the British thoracic oncology group (BTOG) work programme
- Open Access
- 28 May 2026
- Published by Elsevier in Clinical Oncology
- Vol. 56, 104203
Clinical Oncologist and NHS Commissioner Perspectives on Reirradiation for Recurrent Cancer
- 28 May 2026
- Published by Elsevier in Clinical Oncology
- Vol. 56, 104203
Open AccessClinical Oncologist and NHS Commissioner Perspectives on Reirradiation for Recurrent Cancer
- 29 March 2025
- Published by Springer Nature
- p. 155-166
Lung and Mediastinum
- 18 October 2024
- Published by Elsevier in Clinical Oncology
- Vol. 37, 103660
OSAIRIS: Lessons Learned From the Hospital-Based Implementation and Evaluation of an Open-Source Deep-Learning Model for Radiotherapy Image Segmentation
- 18 October 2024
- Published by Elsevier in Clinical Oncology
- Vol. 37, 103660
OSAIRIS: Lessons Learned From the Hospital-Based Implementation and Evaluation of an Open-Source Deep-Learning Model for Radiotherapy Image Segmentation
- 14 May 2024
- Published by Elsevier in Clinical Oncology
- Vol. 36 (7) , 399-401
OncoFlash - Research Updates in a Flash!
- 14 May 2024
- Published by Elsevier in Clinical Oncology
- Vol. 36 (7) , 399-401
OncoFlash - Research Updates in a Flash!
- 26 March 2024
- Published by Elsevier in Clinical Oncology
- Vol. 36 (7) , 402-405
Advancing the Paradigm: Oligometastatic Disease and the Impact of Stereotactic Ablative Body Radiotherapy
- 26 March 2024
- Published by Elsevier in Clinical Oncology
- Vol. 36 (7) , 402-405
Advancing the Paradigm: Oligometastatic Disease and the Impact of Stereotactic Ablative Body Radiotherapy
- 8 January 2024
- Published by Elsevier in Clinical Oncology
- Vol. 36 (2) , 67-69
OncoFlash–Research Updates in a Flash! (Feb 2024)
- 8 January 2024
- Published by Elsevier in Clinical Oncology
- Vol. 36 (2) , 67-69
OncoFlash–Research Updates in a Flash! (Feb 2024)
- Open Access
- 12 December 2023
- Published by Oxford University Press (OUP) in BJR|Open
- Vol. 6 (1) , tzae028
Patient, tumour, and dosimetric factors influencing survival in non-small cell lung cancer patients treated with stereotactic ablative body radiotherapy
Objectives: We aimed to analyse clinical outcomes of peripheral, early-stage non-small cell lung cancer (NSCLC) patients treated with stereotactic ablative body radiotherapy (SABR), and evaluate potential patient, tumour, and dosimetric variables influencing survival. Methods: Data were collected retrospectively from patients treated between September 2012 and December 2016 and followed up until January 2021. Patient demographics, tumour characteristics, SABR dosimetric parameters, and survival data were collected from electronic patient medical records. Descriptive statistics were performed, and SPSS software was used for survival analysis. Results: Eighty-nine patients were included of whom 49.5% were male and 50.5% female. Median age was 74 years. 98.8% of patients had T1-2 tumours and 89.9% underwent 55 Gy in 5 fractions. Median overall survival time was 58.7 months. On uni- and multi-variate analysis, neither patient nor tumour variables showed association with overall survival. However, planning target volume (PTV) and minimum dose to PTV correlated with overall survival. There was a signal for association between mean lung dose and overall survival on multivariate analysis. Conclusions: Our long-term results show SABR is an effective treatment for peripheral, early-stage NSCLC with excellent overall survival, comparable to other series. Our study found only the PTV and minimum dose to PTV had an impact on overall survival, which demonstrates the importance of generating optimal SABR plans. Advances in knowledge: Our work identified lung SABR dosimetric parameters that correlate with survival, which illustrates the importance of producing optimal lung SABR plans.
- 12 December 2023
- Published by Oxford University Press (OUP) in BJR|Open
- Vol. 6 (1) , tzae028
Open AccessPatient, tumour, and dosimetric factors influencing survival in non-small cell lung cancer patients treated with stereotactic ablative body radiotherapy
Objectives: We aimed to analyse clinical outcomes of peripheral, early-stage non-small cell lung cancer (NSCLC) patients treated with stereotactic ablative body radiotherapy (SABR), and evaluate potential patient, tumour, and dosimetric variables influencing survival. Methods: Data were collected retrospectively from patients treated between September 2012 and December 2016 and followed up until January 2021. Patient demographics, tumour characteristics, SABR dosimetric parameters, and survival data were collected from electronic patient medical records. Descriptive statistics were performed, and SPSS software was used for survival analysis. Results: Eighty-nine patients were included of whom 49.5% were male and 50.5% female. Median age was 74 years. 98.8% of patients had T1-2 tumours and 89.9% underwent 55 Gy in 5 fractions. Median overall survival time was 58.7 months. On uni- and multi-variate analysis, neither patient nor tumour variables showed association with overall survival. However, planning target volume (PTV) and minimum dose to PTV correlated with overall survival. There was a signal for association between mean lung dose and overall survival on multivariate analysis. Conclusions: Our long-term results show SABR is an effective treatment for peripheral, early-stage NSCLC with excellent overall survival, comparable to other series. Our study found only the PTV and minimum dose to PTV had an impact on overall survival, which demonstrates the importance of generating optimal SABR plans. Advances in knowledge: Our work identified lung SABR dosimetric parameters that correlate with survival, which illustrates the importance of producing optimal lung SABR plans.
- 10 October 2023
- Published by Elsevier in Clinical Oncology
- Vol. 35 (12) , 773-786
Single-Fraction Stereotactic Ablative Body Radiotherapy for Primary and Extracranial Oligometastatic Cancers
- 10 October 2023
- Published by Elsevier in Clinical Oncology
- Vol. 35 (12) , 773-786
Single-Fraction Stereotactic Ablative Body Radiotherapy for Primary and Extracranial Oligometastatic Cancers
- 3 October 2023
- Published by Elsevier in Clinical Oncology
- Vol. 35 (11) , 695-697
OncoFlash – Research Updates in a Flash! (Nov 2023)
- 3 October 2023
- Published by Elsevier in Clinical Oncology
- Vol. 35 (11) , 695-697
OncoFlash – Research Updates in a Flash! (Nov 2023)